14-PROTEIN SIGNATURE FOR EARLY LUNG CANCER PREDICTION

NEWS: Scientists have identified a 14-protein blood plasma signature that can predict the risk of lung cancer years before tumors become detectableà offering a major breakthrough in early cancer diagnosis.

About the Discovery

  • Published in the journal Cell by a multinational team led by Charles Swanton.
  • Based on analysis of data from 48,000 volunteers in the UK Biobank.
  • Identified a 14-protein signature in blood plasma that serves as an early warning marker for lung cancer.

Key Concepts

  • Plasma Proteomicsà Study of proteins present in blood plasma (plasma proteome) that reflect the health status of different organs.
  • Liquid Biopsyà A non-invasive diagnostic method using blood samples to detect disease-related biomarkers.
  • Traditional Biopsyà Involves collecting tissue directly from the organ and is invasive.

How It Works

  • Blood plasma carries protein signals released by organs throughout the body.
  • Diseased tissues release abnormal proteins that can be detected through advanced analysis.
  • Using AI and machine learning, researchers identified a specific pattern of 14 proteins associated with future lung cancer risk.
  • The signature can predict cancer years before tumors appear on scans.

Key Findings

  • Chronic inflammation caused by smoking and air pollution may activate dormant mutant lung cells, leading to cancer development.
  • Early detection could enable preventive interventions before cancer becomes clinically evident.

Link with CANTOS Trial

  • The CANTOS Trial originally investigated whether reducing inflammation could lower heart attack risk.
  • Retrospective analysis showed that participants with the 14-protein signature who received Canakinumab had about 50% lower risk of lung cancer.
  • However, Canakinumab remains expensive and may cause serious side effects, prompting research into safer alternatives.

Significance

  • Opens the possibility of predictive cancer screening through a simple blood test.
  • Supports the shift from treatment-focused oncology to early detection and prevention.
  • Demonstrates the growing role of AI, proteomics, and liquid biopsy technologies in precision medicine.
Back to Current Affairs